Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2021 | Buy → Neutral | HC Wainwright & Co. |
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
4 - Carisma Therapeutics Inc. (0001485003) (Issuer)
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support of the merger with Carisma. The fact th
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis's Recommendations to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that leading independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), in advance of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. In reaching its concl
Report Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards' Belief That Carisma Merger Maximizes Value for Stockholders Reiterates Support from Several of Sesen Bio's Largest Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that Institutional Shareholder Services ("ISS") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Compan
10-Q - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
8-K - Carisma Therapeutics Inc. (0001485003) (Filer)
Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares increased by 114.3% to $1.05 during Monday's pre-market session. The company's market cap stands at $15.8 million. BridgeBio Pharma (NASDAQ:BBIO) stock moved upwards by 56.39% to $17.0. The market value of their outstanding shares is at $2.5 billion. vTv Therapeutics (NASDAQ:VTVT) stock increased by 48.51% to $1.2. The company's market cap stands at $97.7 million. Kala Pharmaceuticals (NASDAQ:KALA) shares increased by 27.46% to $21.35. The company's market cap stands at $39.9 million. The company's, Q4 earnings came out yesterday. TCR2 Therapeutics (NASDAQ:TCRR) shares rose 25.61% to $1.52. The market value of their outstanding shares
Gainers Secoo Holding Limited (NASDAQ:SECO) rose 44% to $1.44 in pre-market trading after dipping over 31% on Friday. Entera Bio Ltd. (NASDAQ:ENTX) rose 43.1% to $1.46 in pre-market trading after dropping 5% on Friday. Entera Bio recently announced the FDA's acceptance of a Type D meeting review to affirm design of the pivotal, Phase 3 protocol for EB613 PTH mini tablets, as the first oral osteoanabolic treatment of post-menopausal osteoporosis. BuzzFeed, Inc. (NASDAQ:BZFD) rose 20.7% to $1.87 in pre-market trading. BuzzFeed is expected to release its Q4 financial results on Monday, March 13, 2023, after the closing bell. BYND Cannasoft Enterprises Inc. (NASDAQ:BCAN) rose 12.5% to $2.8
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support of the merger with Carisma. The fact tha
SC 13G/A - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13G/A - Carisma Therapeutics Inc. (0001485003) (Subject)
SC 13D/A - Carisma Therapeutics Inc. (0001485003) (Subject)
HC Wainwright & Co. downgraded Sesen Bio from Buy to Neutral
Canaccord Genuity resumed coverage of Sesen Bio with a rating of Buy and set a new price target of $7.00
HC Wainwright reiterated coverage of Sesen Bio with a rating of Buy and set a new price target of $8.00 from $2.25 previously
Declares Special Dividend in the Aggregate of $75 Million Approximately 88% Voted in Favor of the Merger at the Special Meeting Merger on Track to Close on March 7, 2023 Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that its stockholders have voted to approve all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Company's Special Meeting of Stockholders (the "Special Meeting") held earlier today. Dr. Thomas Cannell, President and Chief Executive Officer of Sesen Bio, said, "We are pleased with the outcome of today's Special Meeting and thank our stockholders for their support of the merger with Carisma. The fact th
Positive Recommendations Underscore that Carisma Merger Maximizes Value for Sesen Bio Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Follow ISS and Glass Lewis's Recommendations to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Today Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that leading independent proxy advisory firm Glass, Lewis & Co. ("Glass Lewis") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), in advance of the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") scheduled for March 2, 2023. In reaching its concl
Report Highlights Compelling Strategic Rationale, Estimated Potential Value to Shareholders of $0.88 per Share and Downside Risk of Non-Approval Positive Recommendation Supports Boards' Belief That Carisma Merger Maximizes Value for Stockholders Reiterates Support from Several of Sesen Bio's Largest Stockholders Sesen Bio Board Unanimously Recommends All Stockholders to Vote "FOR" Value Maximizing Merger on WHITE Proxy Card Sesen Bio, Inc. (NASDAQ:SESN) ("Sesen Bio" or the "Company"), today announced that Institutional Shareholder Services ("ISS") recommends that stockholders vote "FOR" all proposals, including the pending merger with Carisma Therapeutics Inc. ("Carisma"), at the Compan
Company hires four experienced leaders across commercial, medical and human resources functions as it works towards launch readiness Company remains on track for potential approval of Vicineum™ in the US in August 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its senior leadership team with the appointment of experienced industry leaders to several key roles: Patricia Drake to Chief Commercial Officer Steve Barbera to Vice President, Market Access Julie Hoff to Vice President, Human Resources Dewey McLin to Vice President, Medical Affairs "I a
Company appoints experienced commercial leader, Lisa LaMond, to oversee sales strategy and execution Selected Syneos Health® as partner for field sales execution in the US Company remains on track for potential approval in the US in August 2021 Sesen Bio (NASDAQ:SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the expansion of its leadership team with the appointment of experienced commercial industry leader, Lisa LaMond, as Vice President, Sales and Corporate Systems. The Company also announced its engagement of leading contract sales organization (CSO), Syneos Health, for field sales support